Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | SLC6A12 | P48065 | 5/20 | 0.41 |
| ▸ | SLC6A11 | P48066 | 5/20 | 0.41 |
| ▸ | SLC6A13 | Q9NSD5 | 5/20 | 0.41 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.41 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.41 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL20211958 | 0.98 | CYP1A2 (0.41) | CYP1A2CYP2D6CYP2C9CYP2C19SLC6A12 | |
| SCHEMBL3022031 | 0.84 | GAA (0.41) | GAAHTTTSHRKDM4EKMT2A | |
| SCHEMBL18027950 | 0.83 | GAA (0.40) | GAAHTTTSHRKDM4EKMT2A | |
| SCHEMBL17945925 | 0.81 | GAA (0.42) | GAAHTTTSHRKDM4EKMT2A | |
| SCHEMBL2092261 | 0.81 | GAA (0.39) | GAAHTTTSHRKDM4EKMT2A | |
| SCHEMBL208074 | 0.80 | GAA (0.36) | CYP1A2CYP2D6CYP2C9CYP2C19GAA | |
| SCHEMBL17709929 | 0.79 | APLNR (0.48) | CYP1A2CYP2D6CYP2C9CYP2C19SLC6A12 | |
| SCHEMBL20572948 | 0.79 | SLC6A12 (0.40) | CYP1A2CYP2D6CYP2C9CYP2C19SLC6A12 | |
| SCHEMBL15641898 | 0.79 | GAA (0.38) | GAAHTTTSHRKDM4EKMT2A | |
| SCHEMBL15231650 | 0.77 | SLC6A12 (0.39) | CYP1A2CYP2D6CYP2C9CYP2C19SLC6A12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025098509-A1 | PYRROLIDINE DERIVATIVE, PHARMACEUTICAL COMPOSITION AND USE THEREOF IN MEDICINE | 康百达（四川）生物医药科技有限公司 | 2025-05-15 | — | — | WO | disclosed |
| EP-4227304-A2 | THIADIAZOLE ANALOGS AND THEIR USE FOR TREATING DISEASES ASSOCIATED WITH A DEFICIENCY OF SMN MOTOR NEURONS | Novartis AG (CH) | 2023-08-16 | — | — | EP | disclosed |
| EP-3736271-B1 | THIADIAZOLE ANALOGS AND THEIR USE FOR TREATING DISEASES ASSOCIATED WITH A DEFICIENCY OF SMN MOTOR NEURONS | NOVARTIS AG (CH) | 2023-03-08 | — | — | EP | disclosed |
| EP-3736271-A1 | THIADIAZOLE ANALOGS AND THEIR USE FOR TREATING DISEASES ASSOCIATED WITH A DEFICIENCY OF SMN MOTOR NEURONS | Novartis AG (CH) | 2020-11-11 | — | — | EP | disclosed |
| EP-2948448-B1 | THIADIAZOLE ANALOGS AND THEIR USE FOR TREATING DISEASES ASSOCIATED WITH A DEFICIENCY OF SMN MOTOR NEURONS | NOVARTIS AG (CH) | 2020-01-08 | — | — | EP | disclosed |
| EP-2948448-A1 | THIADIAZOLE ANALOGS THEREOF AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED-CONDITIONS | Novartis AG (CH) | 2015-12-02 | — | — | EP | disclosed |
| US-20150218175-A1 | THIADIAZOLE ANALOGS THEREOF AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED-CONDITIONS | NOVARTIS AG (CH) | 2015-08-06 | — | — | US | disclosed |
| US-9040712-B2 | Thiadiazole analogs thereof and methods for treating SMN-deficiency-related-conditions | NOVARTIS AG (CH) | 2015-05-26 | — | — | US | disclosed |
| WO-2014116845-A1 | THIADIAZOLE ANALOGS THEREOF AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED-CONDITIONS | NOVARTIS AG (CH) | 2014-07-31 | — | — | WO | disclosed |
| US-20140206661-A1 | THIADIAZOLE ANALOGS THEREOF AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED-CONDITIONS | NOVARTIS AG (CH) | 2014-07-24 | — | — | US | disclosed |
| EP-1263856-A1 | STABILIZER COMPOSITION | BASF AKTIENGESELLSCHAFT (DE) | 2002-12-11 | — | — | EP | disclosed |
| EP-1042399-B1 | USE OF STERICALLY HINDERED AMINES OR STABILISED ETHYLENE POLYMERS IN THE PRODUCTION OF PLASTIC BODIES FOR STORAGE AND TRANSPORT OF VEGETABLE OIL ESTERS | BASELL POLYOLEFINE GMBH (DE) | 2002-07-17 | — | — | EP | disclosed |
| WO-2001057122-A1 | STABILIZER COMPOSITION | BASF AKTIENGESELLSCHAFT (DE) | 2001-08-09 | — | — | WO | disclosed |
| EP-1042399-A1 | USE OF STERICALLY HINDERED AMINES OR STABILISED ETHYLENE POLYMERS IN THE PRODUCTION OF PLASTIC BODIES FOR STORAGE AND TRANSPORT OF VEGETABLE OIL ESTERS | BASF AKTIENGESELLSCHAFT (DE) | 2000-10-11 | — | — | EP | disclosed |
| WO-2000026189-A1 | METHOD FOR PRODUCING NITROXYL COMPOUNDS OF SECONDARY AMINES | BASF AKTIENGESELLSCHAFT (DE) | 2000-05-11 | — | — | WO | disclosed |
| WO-1999032549-A1 | USE OF STERICALLY HINDERED AMINES OR STABILISED ETHYLENE POLYMERS IN THE PRODUCTION OF PLASTIC BODIES FOR STORAGE AND TRANSPORT OF VEGETABLE OIL ESTERS | BASF AKTIENGESELLSCHAFT (DE) | 1999-07-01 | — | — | WO | disclosed |
| US-4396735-A | N-HETEROCYCLIC COMPOUND AND A HETEROCYCLIC ACID HYDRAZIDE | ADEKA ARGUS CHEMICAL CO., LTD. (JP) | 1983-08-02 | — | — | US | disclosed |
| US-4256627-A | COMPRISING COMPLEXES OF POLYMERS HAVING UNITS CONTAINING ALKYLPIPERIDINE GROUPS AND NICKEL OR COBALT CARBOXYLATES OR ENOLATES | CIBA-GEIGY CORPORATION (US) | 1981-03-17 | — | — | US | disclosed |
| EP-0001840-A2 | Stabilising mixtures, process for stabilising synthetic materials against light with these mixtures and synthetic materials so stabilised | CIBA-GEIGY AG (CH) | 1979-05-16 | — | — | EP | disclosed |
| US-3937711-A | POLYMERIC STABILIZERS, POLYOLEFINS | CIBA-GEIGY CORPORATION (US) | 1976-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150218175-A1 | THIADIAZOLE ANALOGS THEREOF AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED-CONDITIONS | SMN1; SMN2, SF3B5, SF3B1 | CYP1A2 1612/4885CYP2D6 2093/4885CYP2C9 1936/4885 |
| US-20140206661-A1 | THIADIAZOLE ANALOGS THEREOF AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED-CONDITIONS | SMN1; SMN2, SF3B5, SF3B1 | CYP1A2 1612/4885CYP2D6 2093/4885CYP2C9 1936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.